HZNP News and Press, Horizon Therapeutics Public Limited Company From 05/04/22

Horizon Therapeutics Public Limited Company (HZNP) Q1 2022 Earnings Conference Call May 04, 2022 08:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor Relations Officer Tim Walbert - Chairman, President & Chief Executive Officer Liz Thompson - Executive Vic...

The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2022 Q1 earnings call. For further details see: Horizon Therapeutics Public Limited Company 2022 Q1 - Results - Earnings Call Presentation

Horizon Therapeutics press release (NASDAQ:HZNP): Q1 Non-GAAP EPS of $1.34 beats by $0.20. Revenue of $885.2M (+158.5% Y/Y) beats by $18.81M. Full-Year 2022 Guidance: Maintaining Full-Year 2022 Net Sales Guidance of $3.9 Billion to $4.0 Billion vs consensus of $3.98B, Representing 22% Gr...

First-Quarter 2022 Results: -- Net Sales of $885.2 Million -- -- GAAP Net Income of $204.3 Million; Adjusted EBITDA of $371.2 Million -- -- TEPEZZA ® (teprotumumab-trbw) Net Sales of $501.5 Million -- -- KRYSTEXXA ® (pegloticase inject...

Horizon Therapeutics (NASDAQ:HZNP) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $1.14 (+3700.0% Y/Y) and the consensus Revenue Estimate is $866.39M (+153.0% Y/Y). Over the last 2 years, HZNP has beaten EPS estimates 88% ...

The shares of Horizon Therapeutics (NASDAQ:HZNP) are trading higher on Tuesday after the commercial-stage biotech announced its Phase 2 trial for rheumatoid arthritis therapy dazodalibep (HZN-4920) met the primary endpoint. The 75 patients who were part of the double-blinded trial were classi...

Detailed results to be presented at upcoming medical congress Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep (HZN-4920) in rheumatoid arthritis (RA) met the primary endpoint. &...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the #RAREis Global Advocate Grant, a new program designed to support the rare disease community by providing financial assistance to U.S. and global patient advocacy groups working to advance, educate and address ...

The European Commission (EC) approved Horizon Therapeutics' (NASDAQ:HZNP) Uplizna as a standalone therapy for adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+). Neuromyelitis optica is a central nervous s...

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death -- -- UPLIZNA is indicated as monotherapy for treatment of adult patients with NMOSD who are anti-aquaporin-4 immunoglobulin G...